News Agency News Aggregator Journalist/Editor Broking House Others
#ResultReview #ASTEC LIFESCIENCES Q3 – YoY = WEAK Produces intermediates for agrochemicals and pharmaceuticals Weak Q with EBITDA And Profit down significantly Rev down 7%; EBITDA down 25% Margins 13.4% vs 16.7% - Down 330 Bps Profit down 42%
#ASTEC ASTEC LIFESCIENCES RESULT
#AstecLifesciences 960, +1% Nicely corrected from highs earlier. Leaving the lower of the Bollinger Bands. MACD Cut-over from bottom. Set for gains.
#AstecLifesciences 1161, +6% Q2 sterling show. Stock to break out of month range!
Good nos-28th oct post 4 till 7 Astec lifesciences Bajaj healthcare-pbt up 5x,pat up 6.5x,H1 eps of 26 Surya roshni-pbt,pat n ocf 2x Orient cement- turnaround,q2 eps of 1.7rs, huge ocf-6x Blue dart-turnaround SIS-q2 eps of 7.3,pbt up 2.2x,ocf at 342cr vs -15cr Mrpl
#asteclife ASTEC LIFESCIENCES RESULT
Astec lifesciences Good quarter Slightly better than q1 runrate which is good Pbt at 24cr vs 7.8cr Pat at 18cr vs 5.2cr Eps of 17.5rs for h1 Decent ocf yoy
Top expected Results today Maruti BPCL Indigo Havells Vodafone Idea TVS Motor BoB Shriram Transport Laurus Labs Canara Bank Tata Chemicals Blue Dart Welspun India Strides Pharma Zensar Tech Welspun Corp Astec Lifesciences JK Paper Orient Cement #stocks #nifty
#LaurusLabs 320, -5%. 52wHigh 343 #VinatiOrganics 1230, -2%. 1419 #NeulandLab1198, flat. 1201 #AstecLifesciences 1082, -3%. 1367 #SuvenPharma 334, -2%. 416 ... API CRAM Contract mfg Intermediate ....story? Is the crack an invitation to buy/add? Or Call to Exit?
Very good report of equirus on astec lifesciences The finer details on the company and industry in this report is a must read
quirus Securities Pvt Ltd initiated coverage of Astec Lifesciences Ltd. with a recommendation of buy. PT set to 1,838 rupees, implies a 48% increase from last price
Equirus Securities Pvt Ltd initiated coverage of Astec Lifesciences Ltd. with a recommendation of buy. PT set to 1,838 rupees, implies a 48% increase from last price
Equirus on astec lifesciences Leader in triazole fungicides Newer mixtures n geographies to aid growth n enhance margins CRAMS in herbicide segment-newer venture and good opportunity size
Astec LifeSciences sold its entire equity stake of 50.10% in Astec Europe Sprl to Charles Delautre-Drouillon and accordingly, Astec Europe Sprl ceases to be a subsidiary of the company. #MOMarketUpdates
Astec LifeSciences reported strong Q1 results. Company reported Revenue up 45.3% to Rs 111.9 crore, Net profit of Rs 16.2 crore from net loss of Rs 1.1 crore, Ebitda up 4.3 times to Rs 28.2 crore and Ebitda margin at 25.2% from 8.4%. #MOMarketUpdates
Astec LifeSciences Limited- Result Declared for First Quarter: Unaudited result for Non-Cumulative
RESULT REVIEW #RALLIS INDIA #ASTEC LIFESCIENCES #ICICI SECURITIES #BALAJI TELEFILMS #HEIDELBERG CEMENT